IMO, this is what RECAF capabilities are.
If you look at the chart I previously referred to, it would be obviously be displaying few if any RECAF levels of early stage cancer samples. The cancer samples have to have been collected for a reason and the likelihood of the graph displayed being much more slanted to later stage cancers is HUGE. If it were possible to collect samples from an equal number of stage1,2,3 and stage 4 cancers and test them for RECAF, the graph would no doubt move far to the left. RECAF will only be able to confirm the mid to later stage cancers that are depicted on that chart.
I have to also question all of the in-house studies that are done. The final jury will not be in until independent blinded trials are run. I truly hope that Abbott does indeed incorporate the test. It is the last and only remaining hope for the company.
In the latest press release, he is basically admitting that the current test could be made more sensitive if it were personalized. By more sensitive, that means to detect early cancers.
I think Kag saw the same problems I am seeing with the test and obviously sold.. When I was first asked to look at the stock, what I saw immediately scared me. This was founded by former horse traders that I have found to be less that candid in their dealings. I got past that and into the RECAF and thought they may indeed have an early cancer detection. I saw the post recently that mentioned the DNA test for cancer that is in trials. IMO, the PSA tests and all other that have a high error rate will disappear when more DNA tests are devised.
If someone wants to ask Moro a question, find out what percentages of 1, 2, 3 and 4th stage cancers are included in that bell curve. If it is an equal distribution, I will be proven wrong.
I'm sure I will be attacked just as Kag was but so be it. Kag just got my attention to look at this a little deeper.
